Dupixent was tested in adolescents and adults with atopic hand-foot dermatitis in what is believed to be the first trial of a biologic therapy in this difficult-to-treat form of the disease.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) announced the second Dupixent (dupilumab) Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) showed that ...